Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $3.70.

According to TipRanks, Lawson is a 4-star analyst with an average return of 7.9% and a 44.92% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Syndax Pharmaceuticals, and Biomea Fusion.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prelude Therapeutics with a $5.00 average price target.

Based on Prelude Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $33.08 million. In comparison, last year the company had a GAAP net loss of $28.64 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prelude Therapeutics (PRLD) Company Description:

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.